ArticleJournal of managed care & specialty pharmacy2021
Adherence to oral oncolytics filled through an internal health-system specialty pharmacy compared with external specialty pharmacies.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The impact of early oral anticancer medication monitoring through electronic patient assessments.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026Trial
- Patient-Tailored Interventions to Improve Specialty Medication Adherence: Results from a Prospective Randomized Controlled Trial.The American journal of medicine · 2023Trial
- Treatment adherence and clinical outcomes of osimertinib in minority patients with advanced EGFR mutated NSCLC.NPJ precision oncology · 2026Article
- Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.Breast cancer research and treatment · 2025Article
- Integrated health system pharmacy role in adherence, persistence, and adverse effect management for oral chronic lymphocytic leukemia therapy.Journal of managed care & specialty pharmacy · 2025Article
- Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste.Journal of managed care & specialty pharmacy · 2024Article
- Comparison of time to treatment initiation of specialty medications between an integrated health system specialty pharmacy and external specialty pharmacies.Journal of managed care & specialty pharmacy · 2024Article
- Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.Digestive diseases and sciences · 2023Article
- The PA System: Is Prior Authorization for Dose Escalation of IBD Biologic Therapy a Tolerable Alternative or a Perpetual Annoyance?Digestive diseases and sciences · 2023Article
- Optimizing HIV PrEP Persistence: Does Your Pharmacy Matter?AIDS and behavior · 2023Article
- Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies.Journal of managed care & specialty pharmacy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.